1921
Volume 99, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

In August 2017, the National Institute of Allergy and Infectious Diseases convened a meeting, entitled “Understanding the Liver-Stage Biology of Malaria Parasites to Enable and Accelerate the Development of a Highly Efficacious Vaccine,” to discuss the needs and strategies to develop a highly efficacious, whole organism–based vaccine targeting the liver stage of malaria parasites. It was concluded that attenuated sporozoite platforms have proven to be promising approaches, and that late-arresting sporozoites could potentially offer greater vaccine performance than early-arresting sporozoites against malaria. New knowledge and emerging technologies have made the development of late-arresting sporozoites feasible. Highly integrated approaches involving liver-stage research, “omics” studies, and cutting-edge genetic editing technologies, combined with in vitro culture systems or unique animal models, are needed to accelerate the discovery of candidates for a late-arresting, genetically attenuated parasite vaccine.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.17-0895
2018-10-03
2018-12-11
Loading full text...

Full text loading...

/deliver/fulltext/14761645/99/4/tpmd170895.html?itemId=/content/journals/10.4269/ajtmh.17-0895&mimeType=html&fmt=ahah

References

  1. World Health Organization, 2017. WHO Global Vaccine Action Plan (GVAP). Available at: www.who.int/entity/immunization/global_vaccine_action_plan/web_gvap_secretariat_report_2017.pdf. Accessed July 30, 2018.
  2. World Health Organization, 2013. WHO Malaria Vaccine Technology Roadmap. Available at: http://www.who.int/immunization/topics/malaria/vaccine_roadmap/en/. Accessed July 30, 2018.
  3. RTS,S Clinical Trials Partnership, 2015. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386: 3145. [Google Scholar]
  4. Mendes AM, Scholzen A, Mueller AK, Khan SM, Sauerwain RW, Prudencio M, , 2017. Whole organism pre-erythrocytic vaccines. Rodrgue A, Mota MM, eds. Malaria: Immune Response to Infection and Vaccination. Cham, Switzerland: Spinger International Publishing, 121–122.
  5. Seder RA, VRC 312 Study Team , 2013. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341: 13591365. [Google Scholar]
  6. Roestenberg M, 2009. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 361: 468477. [Google Scholar]
  7. Mordmüller B, 2017. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature 542: 445449. [Google Scholar]
  8. Ishizuka AS, 2016. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med 22: 614–623. Erratum in: Nat Med 22: 692.
  9. Epstein JE, 2017. Protection against Plasmodium falciparum malaria by PfSPZ vaccine. JCI Insight 2: e89154. [Google Scholar]
  10. Lyke KE, 2017. Attenuated PfSPZ vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc Natl Acad Sci USA 114: 27112716. [Google Scholar]
  11. Sissoko MS, 2017. Safety and efficacy of PfSPZ vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis 17: 498509. [Google Scholar]
  12. Polhemus ME, 2009. Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS One 4: e6465. [Google Scholar]
  13. Butler NS, Schmidt NW, Vaughan AM, Aly AS, Kappe SH, Harty JT, , 2011. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 9: 451462. [Google Scholar]
  14. Spring M, 2013. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine 31: 49754983. [Google Scholar]
  15. Mikolajczak SA, 2014. A next-generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion. Mol Ther 22: 17071715. [Google Scholar]
  16. Fernandez-Ruiz D, 2016. Liver-resident memory CD8+ T cells form a front-line defense against malaria liver-stage infection. Immunity 45: 889902. [Google Scholar]
  17. Sidik SM, 2016. A genome-wide CRISPR screen in toxoplasma identifies essential Apicomplexan genes. Cell 166: 14231435. [Google Scholar]
  18. Roth A, 2018. A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum. Nat Commun 9: 1837. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.17-0895
Loading
/content/journals/10.4269/ajtmh.17-0895
Loading

Data & Media loading...

  • Received : 17 Nov 2017
  • Accepted : 18 Jun 2018

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error